Trial · NCT07476729
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | SR induction EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | SR-MRD good response consolidation DFS | From enrollment until 2 years after end of treatment | timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | HR with CR2 consolidation DSF | From enrollment until 2 years after end of treatment | timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | Isolated extramedullary manifestations: EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | SR induction: Pharmacokinetics Inotuzumab | from enrollment until day 28 | cumulative area under the concentration-time curve (AUC) |
| Secondary | SR induction: MRD | Day 28 of induction | MRD negativity rate after induction quantified by flow- and/or PCR techniques |
| Secondary | SR-MRD good response consolidation: OS | From enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
| Secondary | Isolated extramedullary manifestations: EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Secondary | SR induction: allo-HSCT | week 14 to 20 after enrollment | Proportion of patients requiring allo-HSCT |
| Secondary | SR induction: OS | from enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
| Secondary | SR induction: Toxicity | from enrollement until end of protocol therapy | Toxicity (assessed by CTCAE grades and SAE reports) |
| Secondary | SR induction: CD19 positive cells | week 9 after enrollment | Rate of patients with CD19 positive cells after SCB1 prior to Blinatumomab |
| Secondary | SR-MRD good response consolidation: Toxicity | from enrollment until end of treatment (week 132) | Toxicity (quantified by CTCAE grades and SAE reports) |
| Secondary | Isolated extramedullary manifestations: OS | from enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
| Secondary | Isolated extramedullary manifestations: DFS by MRD | from enrollment until 2 years after end of treatment | timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up by MD after induction (cut-off 10-4) |
| Secondary | HR with CR2 consolidation: OS | from enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
| Secondary | HR with CR2 consolidation: Toxicity | from enrollment until end of treatment (day 100 post HSCT) | Toxicity (assessed by CTCAE grades and SAE reports) |
| Secondary | HR with CR2 consolidation: MRD | week 13 after enrollment | MRD negativity rates before allo-HSCT quantified by flow- and/or PCR techniques |
| Secondary | HR with CR2 consolidation: allo-HSCT | week 14 after enrollment | allo-HSCT rates |
| Secondary | Inotuzumab PK | from enrollment until end of induction (day 28), before and 1 hour after start of inotuzumab infusion | Maximum and through concentrations of inotuzumab |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07476729/registered